Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Moves to Nasdaq Capital Market

NEW YORK (GenomeWeb News) – NeoGenomics has been approved to list its shares on the Nasdaq Capital Market, the Ft. Myers, Fla.-based firm said today.

The company's stock is currently traded on the OTC Bulletin Board under ticker symbol "NGNM." Starting Dec. 10, NeoGenomics will list on Nasdaq under ticker symbol "NEO."

"The transition to the Nasdaq Capital Market is a significant milestone for NeoGenomics and reflects the strong revenue and operating income growth we have achieved over the last several years," NeoGenomics Chairman and CEO Douglas VanOort said in a statement. "We believe this move will increase the visibility and liquidity of our shares in the market."

In late October NeoGenomics reported that its revenues in the third quarter improved 26 percent year over year.

In late afternoon trading today, shares of the company rose 4 percent to $2.81

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.